The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor

Blood Cells, Molecules, and Diseases

Volumn 30, Issue 2, 2003, Pages 177-183

  Hiebert, Scott W ^a,b,c   Reed Inderbitzin, Edward F ^a   Amann, Joseph ^a   Irvin, Brenda ^a   Durst, Kristie ^a   Linggi, Bryan ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HYBRID PROTEIN; MESSENGER RNA; NUCLEAR RECEPTOR COREPRESSOR; PROTEIN AML1 ETO; PROTEIN ETO; PROTEIN MDM2; PROTEIN MSIN3B; PROTEIN P14ARF; PROTEIN P53; PROTEIN SMRT; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR SIN3A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASSAY; BINDING SITE; CELL IMMORTALIZATION; CELL TYPE; CHROMATIN; CHROMOSOME TRANSLOCATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION;

EID: 0038300381     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-9796(03)00021-4     Document Type: Article

References (71)

1. Look A.T. Oncogenic transcription factors in the human acute leukemias. Science. 278:(5340):1997;1059-1064.
2. Miyoshi H., Shimizu K., Kozu T., Maseki N., Kaneko Y., Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA. 88:1991;10431-10434.
3. Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y., Kamada N., Ohki M. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12:1993;2715-2721.
4. Nisson P.E., Watkins P.C., Sacchi N. Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells. Cancer Genet. Cytogenet. 63:1992;81-88.
5. Erickson P., Gao J., Chang K.S., Look T., Whisenant E., Raimondi S., Lasher R., Trujillo J., Rowley J., Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 80:(7):1992;1825-1831.
6. Golub T.R., Barker G.F., Bohlander S.K., Hiebert S.W., Ward D.C., Bray-Ward P., Morgan E., Raimondi S.C., Rowley J.D., Gilliland D.G. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA. 92:(11):1995;4917-4921.
7. Romana S.P., Poirel H., Leconiat M., Flexor M.A., Mauchauffe M., Jonveaux P., Macintyre E.A., Berger R., Bernard O.A. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood. 86:(11):1995;4263-4269.
8. Romana S.P., Mauchauffe M., Le Coniat M., Chumakov I., Le Paslier D., Berger R., Bernard O.A. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood. 85:(12):1995;3662-3670.
9. Shurtleff S.A., Meyers S., Hiebert S.W., Raimondi S.C., Head D.R., Willman C.L., Wolman S., Slovak M.L., Carroll A.J., Behm F., et al. Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood. 85:(12):1995;3695-3703.
10. Liu P., Tarle S.A., Hajra A., Claxton D.F., Marlton P., Freedman M., Siciliano M.J., Collins F.S. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 261:1993;1041-1044.
11. Nucifora G., Begy C.R., Erickson P., Drabkin H.A., Rowley J.D. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc. Natl. Acad. Sci. USA. 90:(16):1993;7784-7788.
12. Sacchi N., Nisson P.E., Watkins P.C., Faustinella F., Wijsman J., Hagemeijer A. AML1 fusion transcripts in t(3;21) positive leukemia evidence of molecular heterogeneity and usage of splicing sites frequently involved in the generation of normal AML1 transcripts . Genes Chromosomes Cancer. 11:1994;226-236.
13. Mitani K., Ogawa S., Tanaka T., Miyoshi H., Kurokawa M., Mano H., Yazaki Y., Ohki M., Hirai H. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 13:1994;504-510.
14. Rowley J.D. The role of chromosome translocations in leukemogenesis. Semin. Hematol. 36:(4 Suppl. 7):1999;59-72.
15. Kania M.A., Bonner A.S., Duffy J.B., Gergen J.P. The Drosophila segmentation gene runt encodes a novel nuclear regulatory protein that is also expressed in the developing nervous system. Genes Dev. 4:1990;1701-1713.
16. Giese K., Kingsley C., Kirshner J.R., Grosschedl R. Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. Genes Dev. 9:1995;995-1008.
17. Bruhn L., Munnerlyn A., Grosschedl R. ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRalpha enhancer function. Genes Dev. 11:1997;640-653.
18. Hernandez-Munain C., Krangel M.S. Regulation of the T-cell receptor delta enhancer by functional cooperation between c-myb and core-binding factors. Mol. Cell. Biol. 14:1994;473-483.
19. Hernandez-Munain C., Krangel M.S. c-Myb and core-binding factor/PEBP2 display functional synergy but bind independently to adjacent sites in the T-cell receptor delta enhancer. Mol. Cell. Biol. 15:1995;3090-3099.
20. Sun W., Graves B.J., Speck N.A. Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins. J. Virol. 69:1995;4941-4949.
21. Zhang D.E., Hetherington C.J., Meyers S., Rhoades K.L., Larson C.J., Chen H.M., Hiebert S.W., Tenen D.G. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol. Cell. Biol. 16:1996;1231-1240.
22. Wotton D., Ghysdael J., Wang S., Speck N.A., Owen M.J. Cooperative binding of ets-1 and core binding factor to DNA. Mol. Cell. Biol. 14:1994;840-850.
23. Mayall T.P., Sheridan P.L., Montminy M.R., Jones K.A. Distinct roles for P-CREB and LEF-1 in TCR alpha enhancer assembly and activation on chromatin templates in vitro. Genes Dev. 11:(7):1997;887-899.
24. Westendorf J.J., Yamamoto C.M., Lenny N., Downing J.R., Selsted M.E., Hiebert S.W. The t(8;21) fusion product, AML-1/ETO, associates with C/EBPα, inhibits C/EBPα-dependent transcription, and blocks granuloctyic differentiation. Mol. Cell. Biol. 18:1998;322-333.
25. Selvamuragan N., Chou W.-Y., Pearman A.T., Pulumati M.R., Partridge N.C. Parathyroid hormone regulates the rat collagenase-3 promoter in osteoblastic cells through the cooperative interaction of the activator protein-1 site and the runt domain binding sequence. J. Biol. Chem. 273:(17):1998;10647-10657.
26. Okuda T., van Deursen J., Hiebert S.W., Grosveld G., Downing J.R. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 84:1996;321-330.
27. Wang Q., Stacy T., Binder M., Marin-Padilla M., Sharpe A.H., Speck N.A. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA. 93:1996;3444-3449.
28. Aronson B.D., Fisher A.L., Blechman K., Caudy M., Gergen J.P. Groucho-dependent and -independent repression activities of Runt domain proteins. Mol. Cell. Biol. 17:(9):1997;5581-5587.
29. Lutterbach B., Westendorf J.J., Linggi B., Isaac S., Seto E., Hiebert S.W. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J. Biol. Chem. 275:(1):2000;651-656.
30. Javed A., Guo B., Hiebert S., Choi J.Y., Green J., Zhao S.C., Osborne M.A., Stifani S., Stein J.L., Lian J.B., van Wijnen A.J., Stein G.S. Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress RUNX (CBF(alpha)/AML/PEBP2(alpha)) dependent activation of tissue-specific gene transcription. J. Cell Sci. 113:(Pt. 12):2000;2221-2231.
31. Lutterbach B., Westendorf J.J., Linggi B., Patten A., Moniwa M., Davie J.R., Huynh K.D., Bardwell V.J., Lavinsky R.M., Rosenfeld M.G., Glass C., Seto E., Hiebert S.W. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol. Cell. Biol. 18:(12):1998;7176-7184.
32. Gelmetti V., Zhang J., Fanelli M., Minucci S., Pelicci P.G., Lazar M.A. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell. Biol. 18:(12):1998;7185-7191.
33. Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. USA. 95:(18):1998;10860-10865.
34. Hildebrand D., Tiefenbach J., Heinzel T., Grez M., Maurer A.B. Multiple regions of eto cooperate in transcriptional repression. J. Biol. Chem. 276:(13):2001;9889-9895.
35. Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., Downing J.R., Meyers S., Hiebert S.W. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21:(19):2001;6470-6483.
36. Meyers S., Downing J.R., Hiebert S.W. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins the runt homology domain is required for DNA binding and protein-protein interactions . Mol. Cell. Biol. 13:(10):1993;6336-6345.
37. Meyers S., Lenny N., Hiebert S.W. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol. Cell. Biol. 15:(4):1995;1974-1982.
38. Lenny N., Meyers S., Hiebert S.W. Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene. 11:(9):1995;1761-1769.
39. Ayer D.E., Lawrence Q.A., Eisenman R.N. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell. 80:1995;767-776.
40. Alland L., Muhle R., Hou H. Jr., Potes J., Chin L., Schreiber-Agus N., DePinho R.A. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature. 387:(6628):1997;49-55.
41. Laherty C.D., Yang W.-M., Sun J.-M., Davie J.R., Seto E., Eisenman R.N. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell. 89:1997;349-356.
42. Nagy L., Kao H.-Y., Chakravarti D., Lin R.J., Hassig C.A., Ayer D.E., Schreiber S.L., Evans R.M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell. 89:1997;373-380.
43. Huynh K.D., Bardwell V.J. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene. 17:(19):1998;2473-2484.
44. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:(5015):1991;49-53.
45. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:(7):1992;1237-1245.
46. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:(6381):1992;80-83.
47. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:(6630):1997;299-303.
48. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:(19):1998;2984-2991.
49. Sherr C.J., Weber J.D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10:(1):2000;94-99.
50. Bates S., Phillips A.C., Clark P.A., Stott F., Peters G., Ludwig R.L., Vousden K.H. p14ARF links the tumour suppressors RB and p53. [letter] Nature. 395:(6698):1998;124-125.
51. de Stanchina E., McCurrach M.E., Zindy F., Shieh S.Y., Ferbeyre G., Samuelson A.V., Prives C., Roussel M.F., Sherr C.J., Lowe S.W. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12:(15):1998;2434-2442.
52. Palmero I., Pantoja C., Serrano M. p19ARF links the tumour suppressor p53 to Ras [letter]. Nature. 395:(6698):1998;125-126.
53. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:(15):1998;2424-2433.
54. Cong F., Zou X., Hinrichs K., Calame K., Goff S.P. Inhibition of v-Ab1 transformation by p53 and p19ARF. Oncogene. 18:(54):1999;7731-7739.
55. Pomerantz J., Schreiber-Agus N., Liegeois N.J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.W., Cordon-Cardo C., DePinho R.A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:(6):1998;713-723.
56. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53 ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways . Cell. 92:(6):1998;725-734.
57. Tao W., Levine A.J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA. 96:(12):1999;6937-6941.
58. Weber J.D., Taylor L.J., Roussel M.F., Sherr C.J., Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell. Biol. 1:(1):1999;20-26.
59. Harvey D.M., Levine A.J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5:(12B):1991;2375-2385.
60. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 91:(5):1997;649-659.
61. Okuda T., Cai Z., Yang S., Lenny N., Lyu C., van Deursen J., Harada H., Downing J. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 91:1998;3134-3143.
62. Rhoades K.L., Hetherington C.J., Harakawa N., Yergeau D.A., Zhou L., Liu L.Q., Little M.T., Tenen D.G., Zhang D.E. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 96:(6):2000;2108-2115.
63. Higuchi M., O'Brien D., Kumaravelu P., Lenny N., Yeoh E.-J., Downing J. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 1:2002;63-74.
64. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:(20):1999;2658-2669.
65. Trecca D., Longo L., Biondi A., Cro L., Calori R., Grignani F., Maiolo A.T., Pelicci P.G., Neri A. Analysis of p53 gene mutations in acute myeloid leukemia. Am. J. Hematol. 46:(4):1994;304-309.
66. Schottelius A., Brennscheidt U., Ludwig W.D., Mertelsmann R.H., Herrmann F., Lubbert M. Mechanisms of p53 alteration in acute leukemias. Leukemia. 8:(10):1994;1673-1681.
67. Gardie B., Cayuela J.M., Martini S., Sigaux F. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood. 91:(3):1998;1016-1020.
68. Linggi B., Muller-Tidow C., van de Locht L., Hu M., Nip J., Serve H., Berdel W.E., van der Reijden B., Quelle D.E., Rowley J.D., Cleveland J., Jansen J.H., Pandolfi P.P., Hiebert S.W. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat. Med. 8:(7):2002;743-750.
69. Meyers S., Lenny N., Sun W., Hiebert S.W. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia. Oncogene. 13:(2):1996;303-312.
70. C. Muller-Tidow, S.K. Metzelder, K. Kugler, J. Schwable, M. Mizuki, B. Steffen, W.-D. Ludwig, A. Heinecke, T. Buchner, W.E. Berdel, H. Serve, Transcriptional profiling of the AML cell cycle identifies the c-Myc-p14ARF pathway as an important predictor for relapse free survival. Submitted.
71. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., Walker H., Wheatley K., Bowen D.T., Burnett A.K., Goldstone A.H., Linch D.C. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials . Blood. 98:(6):2001;1752-1759.